Man Group plc Has $954,000 Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Man Group plc lifted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 191.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 43,302 shares of the company's stock after acquiring an additional 28,457 shares during the quarter. Man Group plc's holdings in Teva Pharmaceutical Industries were worth $954,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Nissay Asset Management Corp Japan ADV increased its stake in Teva Pharmaceutical Industries by 1.1% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 139,049 shares of the company's stock valued at $3,166,000 after buying an additional 1,575 shares during the period. NWI Management LP acquired a new position in Teva Pharmaceutical Industries in the 4th quarter valued at approximately $15,869,000. Noked Israel Ltd increased its stake in Teva Pharmaceutical Industries by 14.6% in the 4th quarter. Noked Israel Ltd now owns 3,285,359 shares of the company's stock valued at $72,409,000 after buying an additional 418,006 shares during the period. Nuveen Asset Management LLC increased its stake in Teva Pharmaceutical Industries by 6.8% in the 4th quarter. Nuveen Asset Management LLC now owns 2,857,007 shares of the company's stock valued at $62,968,000 after buying an additional 182,774 shares during the period. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Teva Pharmaceutical Industries by 74.4% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 138,025 shares of the company's stock valued at $3,042,000 after buying an additional 58,893 shares during the period. Hedge funds and other institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Price Performance

TEVA stock traded up $0.76 during trading on Tuesday, hitting $17.72. 14,880,082 shares of the stock traded hands, compared to its average volume of 10,012,060. Teva Pharmaceutical Industries Limited has a one year low of $12.47 and a one year high of $22.80. The stock has a market cap of $20.09 billion, a price-to-earnings ratio of -12.22, a P/E/G ratio of 1.44 and a beta of 0.62. The company has a 50 day simple moving average of $15.40 and a 200 day simple moving average of $17.36. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. The firm had revenue of $3.89 billion during the quarter, compared to analysts' expectations of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The company's quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.48 EPS. Equities analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on TEVA shares. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their price target for the company from $21.00 to $23.00 in a report on Monday, May 12th. Barclays reduced their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Finally, UBS Group dropped their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $24.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.